The EMBO Journal
 
Advanced search
Journal home
Aims and scope
Current issue
Advance Online Publication
Web Focuses
Archive:-
Browse by issue
Browse by subject
Browse by category
Free online sample issue
Press releases
Authors & Referees
Editorial process
Guide for authors
Submit an article
Guide for referees
Editorial Team, Senior Advisors and Advisory Editorial Board
Contact Editorial office
Customer services
Subscribe
Order sample copy
Purchase articles
Reprints and permissions
Contact NPG
Advertising
EMBO
www.embo.org
Article
Subject Categories: Cell Cycle | Molecular Biology of Disease
The EMBO Journal (2003) 22, 4212–4222, doi:10.1093/emboj/cdg417
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Christian M. Beauséjour1, Ana Krtolica1, Francesco Galimi2, 3, Masashi Narita4, Scott W. Lowe4, Paul Yaswen1 and Judith Campisi1, 5
1 Lawrence Berkeley National Laboratory, MS 84-171, 1 Cyclotron Road, Berkeley, CA 94720, USA
2 The Salk Institute, La Jolla, CA, USA
3 Department of Biomedical Sciences, University of Sassari Medical School, 07100 Sassari, Italy
4 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
5 Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA

To whom correspondence should be addressed
Judith Campisi, jcampisi@lbl.gov

Received 29 November 2002; Revised 12 May 2003; Accepted 1 July 2003.
Abstract
Telomere erosion and subsequent dysfunction limits the proliferation of normal human cells by a process termed replicative senescence. Replicative senescence is thought to suppress tumorigenesis by establishing an essentially irreversible growth arrest that requires activities of the p53 and pRB tumor suppressor proteins. We show that, depending on expression of the pRB regulator p16, replicative senescence is not necessarily irreversible. We used lentiviruses to express specific viral and cellular proteins in senescent human fibroblasts and mammary epithelial cells. Expression of telomerase did not reverse the senescence arrest. However, cells with low levels of p16 at senescence resumed robust growth upon p53 inactivation, and limited growth upon expression of oncogenic RAS. In contrast, cells with high levels of p16 at senescence failed to proliferate upon p53 inactivation or RAS expression, although they re-entered the cell cycle without growth after pRB inactivation. Our results indicate that the senescence response to telomere dysfunction is reversible and is maintained primarily by p53. However, p16 provides a dominant second barrier to the unlimited growth of human cells.
Keywords: cyclin-dependent kinase, pRB, RAS, senescence, telomerase
Send to a friendEmail link to a friend
PDFDownload PDF
Full textFull text
Next article
Previous article
Table of contents
rights and permissionsRights and permissions
order commercial reprintsReprints
ToC alertRegister for table of contents by email
  Privacy policy Copyright © 2003 by the European Molecular Biology Organization